Atacicept 28063 (RMS) extension study

• Research type

  Research Study

• Full title

  An open-label, multicenter phase II extension of study 28063 (ATAMS)to obtain long-term follow-up data in subjects with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension).

• IRAS ID

  18714

• Contact name

  Basil Sharrack

• Contact email

  Basil.Sharrack@sth.nhs.uk

• Sponsor organisation

  Merck Serono International, A branch of Laboratoires Serono SA

• Eudract number

  2008-005021-11

• Clinicaltrials.gov Identifier

  NCT00853762

• Research summary

  Exceeds word count - not published on website

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  09/H0502/89

• Date of REC Opinion

  21 Jul 2009

• REC opinion

  Favourable Opinion